The Latest Breaking News from ResMed

What 5 Analyst Ratings Have To Say About ResMed

ResMed (NYSE:RMD) has observed the following analyst ratings within the last quarter:

Benzinga · Apr 6, 2022

ResMed is our Growth Stock of the Week

Over the last couple of decades, there has been an explosion in ‘lifestyle’ diseases like hypertension, obesity, and diabetes. Over time, these afflictions can start affecting patients’ respiratory and sleep patterns which can exacerbate health issues. Currently, about 5% of men in the US and 3% of women have respiratory…

StockNews.com · Mar 18, 2022

5 Beaten-Down Medtech Stocks to Buy on the Dip

Because record-high inflation and expected interest rate hikes are roiling the equity markets, it could be wise to buy MedTech stocks due to the industry's solid growth prospects and a near-inelastic demand for MedTech products with rising health awareness. So, we believe quality MedTech company stocks ResMed (RMD), Merit Medical…

StockNews.com · Feb 9, 2022

Recap: ResMed Q2 Earnings

ResMed (NYSE:RMD) reported its Q2 earnings results on Thursday, January 27, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Benzinga · Jan 27, 2022

Earnings Preview: ResMed

ResMed (NYSE:RMD) is set to give its latest quarterly earnings report on Thursday, 2022-01-27. Here's what investors need to know before the announcement. Analysts estimate that ResMed will likely report an Earnings Per Share (EPS) of $1.52.

Benzinga · Jan 26, 2022

Is ResMed a Buy Under $250?

Currently trading at less than $250, ResMed Inc. (RMD) exhibited solid fundamental performance in its last reported quarter based on its strong sales growth across its product portfolio. So, given favorable analysts' sentiments about the stock and the company’s strong profitability, is it worth betting on the stock now? Read…

StockNews.com · Jan 25, 2022